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A controlled trial with 
vasopressin analogue (DGAW) 
on cognitive recovery 
immediately after head trauma 
Nicolaas I. Bohnen, MD, PhD; Albert Twijnstra, MD, PhD; and Jellemer Jolles, PhD 
Article abstract-Recent evidence suggests that the vasopressin analogue desglycinamide-arginines-vasopressin 
(DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treat- 
ment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched- 
pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients. 
NEUROLOGY 1993;43:103-106 
Peptides related to the pituitary hormone vaso- 
pressin (VP) influence aspects of memory processes 
and learning in laboratory animals. 1,2 There have 
been several clinical studies with vasopressin and 
related peptides, but the studies differ with respect 
to  the nature of the patients included, methodologic 
characteristics, pharmacokinetic aspects (dose and 
route of administration), and the type of VP ana- 
logue used.3 Some studies reported beneficial 
effects of peptide administration, whereas others 
were n e g a t i ~ e . ~  
The majority of positive findings were obtained 
either in an open, uncontrolled clinical trial with 
patients4 or in placebo-controlled studies with vol- 
u n t e e r ~ . ~ ~ ~  A possible explanation for the discrepant 
findings is that the peptide might have a specific 
action on particular cognitive processes and not on 
others. Most studies where the peptide was ineffec- 
tive involved patients with a complex pattern of 
neuropsychologic deficits or other symptoms sug- 
gestive of profound brain damage. The lack of effect 
in patients with structural brain damage is not sur- 
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prising because lesions of the relevant brain struc- 
tures may have destroyed the sites of action of the 
peptide. 
There have been positive effects in  mild,4z7 as 
opposed to severe, brain t r a ~ r n a . ~ , ~  The efficacy 
may depend on the extent of structural lesions. 
Timsit-Berthier et a17 suggested that the peptide 
effects developed with time, which may indicate 
that the treatment period should be longer than a 
few weeks. We therefore hypothesized that the sub- 
jects of choice for VP treatment would be those 
with early and mild cognitive dysfunction, and the 
duration of the medication should be sufficiently 
long.3 This is supported by investigations using 
desglycinamide-arginines-vasopressin (DGAVP) in 
memory-disturbed patients,1° where peptide effects 
occurred in mild brain trauma but not in patients 
with a severe trauma. 
Mild head injury (MHI) can cause cognitive dys- 
function11-13 which is maximal in the first weeks 
after injury and gradually tends to  res01ve.l~ We 
studied whether an earlier instituted and longer 
treatment with intranasal VP has an effect on cog- 
nitive and subjective recovery in a selected popula- 
tion of patients who had sustained an MHI. 
Methods. Subjects. Consecutively hospitalized patients 
who had sustained an MHI were asked to participate in 
the study on the basis of informed consent. The criteria 
for inclusion in the study were a post-traumatic amnesia 
not exceeding 60 minutes, a period of unconsciousness of 
less than 15 minutes, a Glasgow Coma Score of 13 to 15 
on admission, age between 15 and 70 years, and no seri- 
ous traumatic physical complication. Patients who had 
drunk alcohol a t  the time of the trauma or who had a 
skull fracture or nose trauma were also excluded. None of 
the patients had a history of neuropsychiatric disorder. 
Patients were assigned pairwise to a treatment regi- 
men with either DGAVP or a placebo (carrier). Both 
pat ients  and  staff were blinded to t h e  medication. 
Patients were matched in pairs for age ( f 6  years), sex, 
and education (+1 level15). The study was approved by 
the medical ethical council of the hospital. Fourteen eligi- 
ble pat ients  did not want  to participate, and seven 
pat ients  were excluded because of noncompliance. 
Thirty-two patients completed the study. Each group 
consisted of 16 subjects (nine males and seven females). 
The mean age i n  the DGAVP group was 26.1 years 
(f14.7) and educational level was 5.1 on a 7-point scale 
(kl.0). The corresponding means for the placebo group 
were 27.8 years (k12.4) and 4.5 (kO.9). 
Postconcussive symptoms. A checklist of postconcus- 
sive symptoms was completed, which included headache, 
nausea, dizziness, difficulties with concentration and 
memory, fatigue, and sleep disturbances. As these symp- 
toms also occur in healthy individuals,16 the symptoms 
were scored for the absolute or increased appearance 
after the injury in  comparison with the pretraumatic 
condition. Patients were considered asymptomatic if they 
did not complain of any postconcussive symptoms. 
Psychometric tests. The following tests were used: (1) 
Memory task. A visual, computer-assisted version of the 
Auditory Verbal Learning T e d 7  (AVLT) was presented 
on a portable microcomputer.18 The AVLT was adapted 
for the Dutch language.18J9 The test consists of a list of 
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15 monosyllabic meaningful words, which are presented 
for 1 second at 1-second intervals. At the end of the trial 
the subjects recall the words. Five trials were carried 
out. The variable used in this study was the total num- 
ber of correct words over all trials. Different parallel ver- 
sions of the AVLT were used in each session. 
(2) The Concept Shifting Test20 (CST) is a test of visu- 
al scanning and conceptual tracking, much like the Trail 
Making Test.17 The CST consists of three subtasks. In 
each subtask the subject has to cross out small circles 
containing digits or letters in the correct order. The 
small circles are arranged in a larger circle on a sheet of 
paper. The subject was requested to perform the task as 
quickly as possible. In the first subtask (A) the subject 
has to cross out consecutively numbered (1 to 16) circles, 
in  the second subtask (B) 16 lettered circles (A to P). In 
subtask C, the subject is presented with 16 circles con- 
taining eight digits and eight letters (A to H) and is 
asked to alternate between the two sequences (l-A-Z-B, 
etc.). The amount of extra time needed for subtask C rep- 
resents the concept-shifting score [tC - 0.5 (tA + tB); t = 
time in seconds]. 
(3) The Stroop Color Word Interference T e d 7  consists 
of three subtasks. The test examines the speed at which 
100 color names (yellow, green, red, and blue) are read 
(subtask I) and the speed at which 100 colored spots are 
named (subtask 11). Subtask I11 again involves 100 color 
names, but the printing ink is different from the color 
name; the speed a t  which the color of the printing ink of 
the words is named is taken as the test variable. The 
color word interference score was obtained by subtract- 
ing the time needed for subtask I1 from that of subtask 
I11 (111 - II), and was used as the cognitive parameter. 
Design and procedure. Treatments were administered 
by intranasal spray, each single dose (two puffs) contain- 
ing either 1 mg DGAVP or placebo (kindly donated by 
Organon B.V., Oss, The Netherlands). The subjects were 
instructed to administer themselves four puffs per day 
(two puffs at breakfast time and two puffs at lunch time); 
the daily dose was 2 mg DGAVP. The duration of the 
treatment was 3 months. 
Evaluation of the cognitive performance was done by 
a neuropsychologic assessment a t  six time points within 
the 3-month period. As cognitive recovery after MHI is 
maximal in the first weeks,14 the interval between test 
sessions was shortest immediately after the trauma. This 
interval increased in the later phases after the trauma, 
since we expected to find the greatest changes in perfor- 
mance a t  the beginning of the recovery process. There 
was one pretreatment assessment at day -1. Treatment 
started 2 days after MHI (day 0). Six post-treatment 
assessments were at days 3, 7, 14, 28, 56, and 84. 
Drug safety procedure. Liver and renal functions, elec- 
trolytes, and total blood count were monitored before 
entry into the study and at 3 days, 2 weeks, and 8 weeks 
after the start of treatment. 
Statistical analysis. Test scores were analyzed with 
repeated-measures analysis of variance.21 The only 
grouping factor was the treatment variable (DGAVP ver- 
sus placebo). As recovery after MHI is maximal in the 
first weeks after the injury, tests were performed at 1 
and 3 months after the trauma. Because of the risk of 
increasing the statistical error due to performing multi- 
ple F tests, the Bonferroni correction22 was applied to 
adjust the significance levels. Therefore, a probability 
level of less than 0.005 was considered significant. 
Results. The results of the cognitive tasks are pre- 
Table. Results of neuropsychologic test (means k SD) 
I 
AVLT-tot Concept shifting Stroop interference 1 No. Session DGAVP Placebo DGAVP Placebo DGAVP Placebo 
1 Day 3 43.9 * 5.4 42.8 f 7.6 10.6 f 5.5 8.9 f 6.4 34.6 f 12.1 31.2f 11.9 
2 Day 7 40.8 f 8.4 43.7 * 7.4 8.3 f 4.5 10.0 f 8.2 31.4 f 15.5 21.8 k 5.6 
4 Day 28 47.3 2 9.2l 48.8 f 8.12 7.2 * 7.g5 7.1 f 4.36 25.6 f 8.59 19.7 k 8.31° 
5 Day 56 51.9 k 9.2 54.0 f 7.8 4.9 f 4.5 7.4 f 6.5 22.4 f 11.5 19.2 k 4.3 
6 Day 84 50.6 f 12.33 52.0 2 9.64 9.3 _t 6.57 6.1 f 5.18 24.2 k 8.711 19.8 * 4.912 
F-values (repeated measures ANOVA) of the overall time effect and time X DGAVP interaction terms are  presented (Bonferroni corrected 
significance levels). AVLT-tot = total number of correctly recalled words; Stroop interference = Stroop color word interference score. 
3 Day 14 48.0 f 9.4 48.4 f 8.4 10.6 f 5.8 8.6 * 7.1 27.0 5 10.9 22.0 f 5.9 
1 Time: F(3,281= 11.66, p < 0.001. 2 Time X DGAVP: F(3,28) <1, NS. 
3 Time: F(5,25) = 13.02, p < 0.001. 4 Time X DGAW: F(5,25) <1, NS. 
5 Time: F(3,24) = 1, NS. 6 Time X DGAVP: F(3,24) <1, NS. 
7 Time: F(5,23) = 1.27, NS. 8 Time X DGAVP: F(5,23) <1, NS. 
9 Time: F(3,27) = 1 3 . 5 4 , ~  < 0.001. 10 Time X DGAVP: F(3,27) = 1.11, NS. 
11 Time: F(3,26) = 10 .11 ,~~  < 0.001. 12  Time X DGAVP: F(3,26) = 2.24, NS. 
sented in the table. Repeated-measures analysis of 
variance demonstrated a significant time effect for 
the scores of the verbal memory test after 1 month 
[F(3,28) = 11.66, p < 0.0011 and 3 months [F(5,25) = 
13.02, p < 0.0011. Similar findings were done for 
the Stroop interference measure for 1 month 
[F(3,27) = 13.54, p < 0.0011 and for  3 months 
[F(3,26) = 10.11, p < 0.0011, indicating that there 
was a significant improvement after the injury. 
There was no significant time effect for the con- 
cept-shifting score for 1 month [F(3,24) = 1, NSI 
and for 3 months [F(5,23) = 1.27, NSI after the 
injury (table). 
With respect to the DGAVP treatment, there 
was no significant time X DGAVP interaction for 
any of the cognitive parameters at 1 or 3 months 
after the trauma (table). This indicates that  the 
groups did not differ in the mean rate of cognitive 
recovery from MHI. 
There was no significant difference between the 
two  groups in  the  number of asymptomatic 
patients at 1 month (chi-square = 0.67; NS) and 3 
months (chi-square = 0.01; NS). 
Discussion. The present results do not support 
the hypothesis that DGAVP affects the early cogni- 
tive recovery from an MHI. Recent evidence sug- 
gests that around 25% of patients with MHI may 
have persistent cognitive and neurobehavioral 
sequelae at 6 months p o s t i n j ~ r y . ~ ~ , ~ ~  This and the 
positive findings in the Hijman et  a1 studylo of 
patients with persistent postconcussional symp- 
toms suggest that a possible DGAVP effect may be 
confined to a subgroup of trauma patients with dif- 
ferent profiles of cognitive dysfunctions. 
Future studies with DGAVP should focus on 
selected groups of mildly head-injured patients suf- 
fering from the persistent postconcussional syn- 
drome to test the hypothesis from earlier research 
that positive findings with DGAVP are confined to 
this patient population.1° 
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Clock-drawing test and 
unilateral spatial neglect 
S. Ishiai, MD; M. Sugishita, DMS, DHS; T. Ichikawa, MD; S. Gono, MD; and S. Watabiki, MD 
~~ ~~ 
Article abstractwe investigated the ability of 25 pat ients  wi th  left uni la teral  spat ia l  neglect t o  make a clock face by  
put t ing numbers  inside a pr inted circle. Impai rment  seen in this clock-drawing test did not  parallel neglect severity as 
judged b y  results of the line-cancellation a n d  line-bisection tests, as well as the copying of a daisy. The score for clock 
drawing correlated highly wi th  the verbal WAIS score. Most neglect patients wi th  a verbal I& of 8 7  or  more could d r a w  
a clock face fairly well a n d  used planning in placing the numbers  12, 3, 6, a n d  9 before the others. In clock drawing, 
verbal intelligence m a y  compensate for left unilateral spatial neglect. We therefore recommend use of the line-cancella- 
tion a n d  line-bisection tests, as well as the copying test, b u t  do not  recommend use of the clock-drawing test in the 
diagnosis of left unilateral spatial neglect. 
NEUROLOGY 1993;43:106-110 
The clock-drawing test has been used as a tradi- 
tional diagnostic measure of unilateral spatial 
neglect.1-6 Patients with left unilateral spatial 
neglect may place all 12 numbers on the right half 
of a clock face or place correctly only the hours from 
12 to 6 on the right ~ i d e . ~ , ~ , ~  Some patients who 
demonstrate typical left unilateral spatial neglect 
in other tests, however, show no or only slight 
impairment in  clock d r a ~ i n g . ~  Pat ients  with 
dementia may have difficulty in drawing a clock 
face.s-10 Intelligence, therefore, may also influence 
the performances of neglect patients in the clock- 
drawing test. We investigated the role of intellectu- 
al decline in the ability to  make clock drawings and 
reappraised the efficacy of the clock-drawing test as 
a diagnostic measure of left unilateral spatial 
neglect by comparing it with other tests of neglect. 
Methods. Subjects. Twenty-five pat ients  with left unilat- 
eral spat ia l  neglect took p a r t  in the study. All were fully 
r ight-handed in the activities included i n  the questions 
f o r  h a n d e d n e s s  in the Western A p h a s i a  B a t t e r y ,  
J a p a n e s e  edition." Ages ranged f r o m  47 t o  79  y e a r s  
(mean,  61.4 years), and the dura t ion  af ter  onset  of the 
condition w a s  from 1 to 22 months  (mean,  7.4 months). 
The diagnosis  of les ions was m a d e  from results of CT 
examinat ions.  Twenty- three  subjects  h a d  r i g h t  middle  
cerebral a r te ry  terr i tory infarcts  that involved the pari- 
etal a n d  temporal  lobes and ,  t o  some extent, the frontal 
lobe. Two had deep lesions-an anter ior  choroidal a r te ry  
terr i tory infarction a n d  a thalamic hemorrhage. All sub- 
jects  had apparent left hemiparesis and used the r ight  
h a n d  in each test. Judgment of verbal a n d  performance 
i n t e l l i g e n c e  w a s  based o n  the W e c h s l e r  A d u l t  
Intelligence Scale (WAIS), Japanese edition.12 Informed 
consent for testing w a s  obtained from all subjects. 
Clock-drawing test. We a s k e d  the subjects  t o  place 
- 
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